Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group

ObjectiveThis prospective real-world study, conducted by the Greek Research Alliance for the Study of Headache and Pain (GRASP), aimed to evaluate the efficacy, tolerability and safety of subcutaneous galcanezumab 240 mg in reducing the frequency and clinical burden of CH attacks at week 4.MethodsTh...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michail Vikelis, Andreas A. Argyriou, Maria Chondrogianni, Aikaterini Foska, Dimitrios Rikos, Christos Tsironis, Panagiotis Soldatos, Maria Koutsokera, Emmanouil V. Dermitzakis
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-01-01
Edice:	Frontiers in Neurology
Témata:	chronic cluster headache effectiveness episodic cluster headache galcanezumab prevention safety
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fneur.2025.1748498/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!